Cover Image
市場調查報告書

疾病分析:頭頸癌

Disease Analysis: Head and Neck Cancer

出版商 Datamonitor Healthcare 商品編碼 603915
出版日期 內容資訊 英文 309 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
疾病分析:頭頸癌 Disease Analysis: Head and Neck Cancer
出版日期: 2017年12月01日 內容資訊: 英文 309 Pages
簡介

本報告提供頭頸癌市場相關調查分析,提供市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:頭頸癌 (2017年12月1日出版)

  • 摘要整理
  • 最新預測更新
  • 市場動態
  • 預測與未來趨勢
  • 市場定義·手法
  • 一次調查手法
  • 參考文獻
  • 產品簡介 (後期) :BAVENCIO
  • 產品簡介:ERBITUX
  • 產品簡介 (後期) :GILOTRIF
  • 產品簡介 (後期) :IMFINZI
  • 產品簡介:KEYTRUDA
  • 產品簡介 (後期) :MULTIKINE
  • 產品簡介 (後期) :OPDIVO
  • 參考文獻

治療:頭頸癌 (2017年9月15日出版)

  • 摘要整理
  • 一次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢

流行病學:頭頸癌 (2017年8月8日出版)

  • 摘要整理
  • 疾病的背景
  • 手法
  • 預測
  • 流行病學者的考察
  • 優勢與限制
  • 參考文獻
  • 附錄

上市藥:頭頸癌 (2017年12月1日出版)

  • 摘要整理
  • 產品概要
  • 產品簡介:ERBITUX
  • 產品簡介:KEYTRUDA
  • 產品簡介:OPDIVO

開發平台:頭頸癌 (2017年12月1日出版)

  • 摘要整理
  • 臨床開發平台概要
  • 產品簡介 (後期) :BAVENCIO
  • 產品簡介 (後期) :GILOTRIF
  • 產品簡介 (後期) :IMFINZI
  • 產品簡介 (後期) :MULTIKINE
目錄
Product Code: DMKC12793

DISEASE OVERVIEW

Head and neck cancer is the sixth most common cancer worldwide, and includes malignancies that can originate in the oral cavity, salivary glands, sinuses, and throat. Around 90% of cases have an epithelial origin, which present as squamous cell carcinomas. Environmental factors such as tobacco smoking and alcohol consumption greatly increase the risk of developing head and neck cancers. If diagnosed at an early stage, treatment for these cancers can be curative; however, the majority of patients are diagnosed when the disease is advanced, resulting in the need for more than one treatment modality.

MARKET SNAPSHOT

  • The head and neck cancer market is projected to reach $2.8bn in value by 2026, with growth driven by immunotherapies.
  • Erbitux continues to be the primary targeted therapy prescribed for the treatment of advanced head and neck cancer.
  • The incident population of this common cancer is predicted to increase over the forecast period of 2016-36.
  • Erbitux's position as the leading targeted therapy for SCCHN is being challenged as immunotherapies enter the market.
  • Immunotherapy developers will look to minimize direct competition in SCCHN by targeting new patient settings.

TABLE OF CONTENTS

  • FORECAST: HEAD AND NECK CANCER (Published on 01 December 2017)
  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • PRODUCT PROFILE (LATE STAGE): BAVENCIO
  • PRODUCT PROFILE: ERBITUX
  • PRODUCT PROFILE (LATE STAGE): GILOTRIF
  • PRODUCT PROFILE (LATE STAGE): IMFINZI
  • PRODUCT PROFILE: KEYTRUDA
  • PRODUCT PROFILE (LATE STAGE): MULTIKINE
  • PRODUCT PROFILE: OPDIVO
  • BIBLIOGRAPHY
  • TREATMENT: HEAD AND NECK CANCER (Published on 15 September 2017)
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • EPIDEMIOLOGY: HEAD AND NECK CANCER (Published on 08 August 2017)
  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES
  • MARKETED DRUGS: HEAD AND NECK CANCER (Published on 01 December 2017)
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ERBITUX
  • PRODUCT PROFILE: KEYTRUDA
  • PRODUCT PROFILE: OPDIVO
  • PIPELINE: HEAD AND NECK CANCER (Published on 01 December 2017)
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): BAVENCIO
  • PRODUCT PROFILE (LATE STAGE): GILOTRIF
  • PRODUCT PROFILE (LATE STAGE): IMFINZI
  • PRODUCT PROFILE (LATE STAGE): MULTIKINE

LIST OF FIGURES

  • Figure 1: SCCHN - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for SCCHN
  • Figure 3: SCCHN market value across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: SCCHN market value across the US, Japan, and five major EU markets, by class, 2017-26
  • Figure 5: Sales of PD-1/PD-L1 inhibitors for SCCHN across the US, Japan, and five major EU markets, by brand, 2017-26
  • Figure 6: Sales of key therapies for SCCHN across the US, Japan, and five major EU markets, by status, 2017-26
  • Figure 7: Patient-based forecast methodology for SCCHN
  • Figure 8: Price sources and calculations, by country
  • Figure 9: Bavencio for head and neck cancer - SWOT analysis
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Bavencio for SCCHN
  • Figure 11: Datamonitor Healthcare's drug assessment summary of Bavencio for SCCHN
  • Figure 12: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 13: Erbitux for head and neck cancer - SWOT analysis
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Erbitux for SCCHN
  • Figure 15: Datamonitor Healthcare's drug assessment summary of Erbitux for SCCHN
  • Figure 16: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 17: Gilotrif for head and neck cancer - SWOT analysis
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Gilotrif for SCCHN
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Gilotrif for SCCHN
  • Figure 20: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 21: Imfinzi for head and neck cancer - SWOT analysis
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Imfinzi for SCCHN
  • Figure 23: Datamonitor Healthcare's drug assessment summary of Imfinzi for SCCHN
  • Figure 24: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 25: Keytruda for head and neck cancer - SWOT analysis
  • Figure 26: Datamonitor Healthcare's drug assessment summary of Keytruda for SCCHN
  • Figure 27: Datamonitor Healthcare's drug assessment summary of Keytruda for SCCHN
  • Figure 28: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 29: Multikine for head and neck cancer - SWOT analysis
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Multikine for SCCHN
  • Figure 31: Datamonitor Healthcare's drug assessment summary of Multikine for SCCHN
  • Figure 32: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 33: Opdivo for head and neck cancer - SWOT analysis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Opdivo for SCCHN
  • Figure 35: Datamonitor Healthcare's drug assessment summary of Opdivo for SCCHN
  • Figure 36: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 37: HPV screening rates and outcomes among SCCHN patients, by country
  • Figure 38: Proportion of prevalent SCCHN patients in each stage of disease, by country
  • Figure 39: Proportion of Stage I and Stage II SCCHN patients receiving each treatment type, by country
  • Figure 40: Percentage of Stage III SCCHN patients receiving each treatment type, by country
  • Figure 41: Percentage of Stage III SCCHN patients receiving neoadjuvant therapy, adjuvant therapy, or both, by country
  • Figure 42: Top three regimens used in the adjuvant treatment of Stage III SCCHN patients, by country
  • Figure 43: Percentage of Stage IV SCCHN patients receiving each treatment type, by country
  • Figure 44: Top three regimens used in the first-line treatment of Stage IV SCCHN patients who receive pharmacological therapy without surgery, by country
  • Figure 45: Percentage of Stage IV SCCHN patients who progress from first- to second-line therapy or from second- to thirdline therapy, by country
  • Figure 46: Top three regimens used for the second-line treatment of Stage IV SCCHN patients, by country
  • Figure 47: Percentage of local relapse SCCHN patients receiving each treatment type, by country
  • Figure 48: Top three regimens used in the first-line treatment of local relapse SCCHN patients receiving pharmacological therapy without surgery, by country
  • Figure 49: Top three regimens used in the second-line treatment of local relapse SCCHN patients, by country
  • Figure 50: Percentage of distant relapse SCCHN patients receiving each treatment type, by country
  • Figure 51: Top three regimens used in the first-line treatment of distant relapse SCCHN patients who receive pharmacological therapy without surgery, by country
  • Figure 52: Top three regimens used in the second-line treatment of distant relapse SCCHN patients, by country
  • Figure 53: Trends in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
  • Figure 54: Absolute change in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
  • Figure 55: Age-specific trends in incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 56: Erbitux for head and neck cancer - SWOT analysis
  • Figure 57: Datamonitor Healthcare's drug assessment summary of Erbitux for SCCHN
  • Figure 58: Datamonitor Healthcare's drug assessment summary of Erbitux for SCCHN
  • Figure 59: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 60: Keytruda for head and neck cancer - SWOT analysis
  • Figure 61: Datamonitor Healthcare's drug assessment summary of Keytruda for SCCHN
  • Figure 62: Datamonitor Healthcare's drug assessment summary of Keytruda for SCCHN
  • Figure 63: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 64: Opdivo for head and neck cancer - SWOT analysis
  • Figure 65: Datamonitor Healthcare's drug assessment summary of Opdivo for SCCHN
  • Figure 66: Datamonitor Healthcare's drug assessment summary of Opdivo for SCCHN
  • Figure 67: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 68: Bavencio for head and neck cancer - SWOT analysis
  • Figure 69: Datamonitor Healthcare's drug assessment summary of Bavencio for SCCHN
  • Figure 70: Datamonitor Healthcare's drug assessment summary of Bavencio for SCCHN
  • Figure 71: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 72: Gilotrif for head and neck cancer - SWOT analysis
  • Figure 73: Datamonitor Healthcare's drug assessment summary of Gilotrif for SCCHN
  • Figure 74: Datamonitor Healthcare's drug assessment summary of Gilotrif for SCCHN
  • Figure 75: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 76: Imfinzi for head and neck cancer - SWOT analysis
  • Figure 77: Datamonitor Healthcare's drug assessment summary of Imfinzi for SCCHN
  • Figure 78: Datamonitor Healthcare's drug assessment summary of Imfinzi for SCCHN
  • Figure 79: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 80: Multikine for head and neck cancer - SWOT analysis
  • Figure 81: Datamonitor Healthcare's drug assessment summary of Multikine for SCCHN
  • Figure 82: Datamonitor Healthcare's drug assessment summary of Multikine for SCCHN
  • Figure 83: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: SCCHN market value across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 2: SCCHN market value across the US, Japan, and five major EU markets, by class ($m), 2017-26
  • Table 3: Sales of PD-1/PD-L1 inhibitors for SCCHN across the US, Japan, and five major EU markets, by brand ($m), 2017-26
  • Table 4: Sales of key therapies for SCCHN across the US, Japan, and five major EU markets, by status ($m), 2017-26
  • Table 5: Summary of drug classes and molecules included in Datamonitor Healthcare's SCCHN patient-based forecast
  • Table 6: Exchange rates used for calculating prices
  • Table 7: Patent expiry dates for key marketed brands in SCCHN across the US, Japan, and five major EU markets, 2017-26
  • Table 8: Estimated launch dates of key pipeline products and marketed brands in SCCHN across the US, Japan, and five major EU markets, 2017-26
  • Table 9: Medical oncologists, otolaryngologists, and ENT surgeons surveyed for the head and neck cancer primary research study, 2017
  • Table 10: Bavencio drug profile
  • Table 11: Bavencio Phase III trials in head and neck cancer
  • Table 12: Bavencio early-phase data in head and neck cancer
  • Table 13: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 14: Bavencio patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 15: Erbitux drug profile
  • Table 16: Erbitux pivotal trial data in head and neck cancer
  • Table 17: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 18: Erbitux patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 19: Gilotrif drug profile
  • Table 20: Gilotrif Phase III trials in head and neck cancer
  • Table 21: Gilotrif Phase III trial data in head and neck cancer
  • Table 22: Gilotrif early-phase data in head and neck cancer
  • Table 23: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 24: Gilotrif patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 25: Imfinzi drug profile
  • Table 26: Imfinzi Phase III trials in head and neck cancer
  • Table 27: Imfinzi early-phase data in head and neck cancer
  • Table 28: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 29: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 30: Keytruda drug profile
  • Table 31: Keytruda pivotal trial data in head and neck cancer
  • Table 32: Keytruda ongoing late-phase trials in head and neck cancer
  • Table 33: Keytruda early-phase data in head and neck cancer
  • Table 34: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 35: Keytruda patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 36: Multikine drug profile
  • Table 37: Multikine Phase III trials in head and neck cancer
  • Table 38: Multikine early-phase data in head and neck cancer
  • Table 39: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 40: Multikine patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 41: Opdivo drug profile
  • Table 42: Opdivo pivotal trial data in head and neck cancer
  • Table 43: Opdivo ongoing late-phase trials in head and neck cancer
  • Table 44: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 45: Opdivo patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 46: Physicians surveyed for the head and neck cancer primary research study, 2017
  • Table 47: Oral cavity and pharynx cancer five-year survival rates, by stage at diagnosis, 2007-13
  • Table 48: TNM stage classification
  • Table 49: Leading treatments for SCCHN
  • Table 50: Head and neck cancer site codes according to ICD-10
  • Table 51: Cancer registry databases used as a source of HNC incidence data, by country
  • Table 52: Forecasting methodology for HNC incidence, by country, age group, and gender
  • Table 53: Sources of survival data used to estimate HNC prevalence, by country/region
  • Table 54: Diagnosed incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 55: Age-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
  • Table 56: Gender-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
  • Table 57: Validation of forecast estimates against benchmark estimates
  • Table 58: Profiled key marketed drugs for head and neck cancer
  • Table 59: Erbitux drug profile
  • Table 60: Erbitux pivotal trial data in head and neck cancer
  • Table 61: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 62: Erbitux patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 63: Keytruda drug profile
  • Table 64: Keytruda pivotal trial data in head and neck cancer
  • Table 65: Keytruda ongoing late-phase trials in head and neck cancer
  • Table 66: Keytruda early-phase data in head and neck cancer
  • Table 67: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 68: Keytruda patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 69: Opdivo drug profile
  • Table 70: Opdivo pivotal trial data in head and neck cancer
  • Table 71: Opdivo ongoing late-phase trials in head and neck cancer
  • Table 72: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 73: Opdivo patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 74: Profiled pipeline products in development for head and cancer
  • Table 75: Bavencio drug profile
  • Table 76: Bavencio Phase III trials in head and neck cancer
  • Table 77: Bavencio early-phase data in head and neck cancer
  • Table 78: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 79: Bavencio patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 80: Gilotrif drug profile
  • Table 81: Gilotrif Phase III trials in head and neck cancer
  • Table 82: Gilotrif Phase III trial data in head and neck cancer
  • Table 83: Gilotrif early-phase data in head and neck cancer
  • Table 84: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 85: Gilotrif patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 86: Imfinzi drug profile
  • Table 87: Imfinzi Phase III trials in head and neck cancer
  • Table 88: Imfinzi early-phase data in head and neck cancer
  • Table 89: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 90: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 91: Multikine drug profile
  • Table 92: Multikine Phase III trials in head and neck cancer
  • Table 93: Multikine early-phase data in head and neck cancer
  • Table 94: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 95: Multikine patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Back to Top